On this page
What it is
What Is Semaglutide?Semaglutide is a synthetic peptide that mimics GLP-1 (glucagon-like peptide-1), a hormone your body naturally produces after eating. It's manufactured by Novo Nordisk and sold under several brand names:
What people research it for
What is semaglutide?
Human studiesSemaglutide is a GLP-1 receptor agonist — a synthetic version of a naturally occurring hormone that regulates appetite and blood sugar. It is the active ingredient in Wegovy (weight loss) and Ozempic (type 2 diabetes), and was the first once-weekly injectable medication approved specifically for chronic weight management in adults with obesity.
How much weight can you lose on semaglutide?
Human studiesClinical trials show an average of ~15% body weight loss at the standard 2.4 mg dose over 68 weeks (STEP 1 trial). The newly approved 7.2 mg high-dose formulation (Wegovy HD) showed ~21% average weight loss in the STEP UP trial.
What are the side effects of semaglutide?
Human studiesThe most common side effects are gastrointestinal: nausea (affects up to 44% of patients), vomiting, diarrhea, and constipation. These are typically most pronounced during dose escalation and improve over time. Serious but rare side effects include pancreatitis and gallbladder disease.
How it works
How Does Semaglutide Work?Semaglutide is 94% structurally identical to the GLP-1 hormone your body naturally produces. But unlike natural GLP-1 — which breaks down in minutes — semaglutide is engineered to last about a week in your bloodstream. It works through multiple interconnected mechanisms:
1. Appetite Suppression (Central Nervous System)
Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem — the regions that control hunger and satiety. It activates anorexigenic signaling pathways, making you feel full sooner and reducing food cravings. Most people on semaglutide report a significant reduction in appetite and “food noise” — the persistent thoughts about food that many people with obesity experience. This is the primary driver of weight loss.
2. Delayed Gastric Emptying
Semaglutide slows the rate at which food leaves your stomach. This means you feel physically full for longer after eating, which naturally reduces portion sizes and snacking.
3. Reduced Glucagon Secretion
Semaglutide suppresses glucagon — the hormone that tells your liver to release stored glucose. This helps stabilize blood sugar levels and reduces the insulin spikes that can drive hunger.
4. Enhanced Insulin Secretion (Glucose-Dependent)
When blood sugar rises after eating, semaglutide boosts insulin production. Crucially, this effect is glucose-dependent — it only increases insulin when blood sugar is elevated, which significantly reduces the risk of hypoglycemia.
The net effect: You eat less because you're genuinely less hungry. You feel full faster and stay full longer. Your blood sugar stabilizes. Over time, this sustained caloric deficit produces significant weight loss.
What the research actually shows
Semaglutide's weight loss effects have been studied in the STEP (Semaglutide Treatment Effect in People with Obesity) trial program — one of the largest obesity medication trial programs ever conducted.
Published
NEJM, 2021
Guide status and key facts
Key Facts at a Glance
- Drug class
- GLP-1 receptor agonist
- Administration
- Weekly injection or daily oral tablet
- FDA approval
- June 2021 weight loss; March 2024 CV risk reduction
- Average loss
- ~15% body weight (68 wks)
- Manufacturer
- Novo Nordisk
- Higher dose
- 7.2 mg FDA approved March 19, 2026
Clinical Trial Evidence
Semaglutide's weight loss effects have been studied in the STEP (Semaglutide Treatment Effect in People with Obesity) trial program — one of the largest obesity medication trial programs ever conducted.
STEP 1 — The Landmark Trial
Published
NEJM, 2021
Participants
1,961 adults
Duration
68 weeks
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Semaglutide 2.4 mg/week vs. placebo, both with lifestyle intervention.
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Average weight loss | 14.9% | 2.4% |
| ≥10% body weight lost | 69.1% | 12.0% |
| ≥20% body weight lost | 32.0% | 1.7% |
For a 250-pound person, 14.9% = roughly 37 pounds lost over 68 weeks.
| Trial | Population | Avg. Loss | Key Finding |
|---|---|---|---|
| STEP 2 | Obesity + T2 diabetes | 9.6% | Lower loss with diabetes; still clinically significant |
| STEP 3 | Obesity + intensive therapy | 16.0% | Behavioral support boosts results further |
| STEP 4 | Discontinuation study | — | Stopping = regaining ~6.9% of body weight |
| STEP 5 | 2-year duration | ~15% | Weight loss sustained at 2 years |
| STEP UP | Higher dose (7.2 mg) | ~21% | 7.2 mg FDA approved March 19, 2026 |
What the trials tell us:
- Most weight loss happens in the first 6 months; results plateau around months 12–16
- Average loss is ~15% at standard dose, ~21% at the newly approved 7.2 mg dose
- Weight returns if you stop the medication (this is a chronic treatment)
- Individual results vary significantly — some lose 25%+, others 5%
- Combining medication with diet and exercise improves outcomes
Semaglutide and Heart Protection: What SELECT Actually Showed
Semaglutide is no longer only a weight-loss drug. Wegovy also has a cardiovascular risk-reduction indication for adults with established cardiovascular disease and overweight or obesity. The important caveat is eligibility. The strongest evidence is not for every person trying to lose weight. It is for people who already have cardiovascular disease.
Quick answer
In SELECT, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% versus placebo in adults age 45 or older with BMI ≥27, established cardiovascular disease, and no diabetes. Events occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group over a mean follow-up of 39.8 months.
| Question | SELECT answer |
|---|---|
| Who was studied? | 17,604 adults, age 45+, BMI ≥27, established cardiovascular disease, no diabetes |
| Dose | Semaglutide 2.4 mg once weekly, the Wegovy weight-management dose |
| Main endpoint | Cardiovascular death, nonfatal heart attack, or nonfatal stroke |
| Result | 6.5% with semaglutide vs. 8.0% with placebo, HR 0.80, 95% CI 0.72 to 0.90 |
| Treatment discontinuation | Adverse events led to permanent discontinuation in 16.6% with semaglutide vs. 8.2% with placebo |
FDA and NICE status
The FDA approved Wegovy in March 2024 to reduce cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity. NICE guidance TA1152 recommends semaglutide up to 2.4 mg weekly for adults with established cardiovascular disease and BMI ≥27, alongside reduced-calorie diet and increased physical activity, subject to the NHS commercial arrangement.
What this does not prove
SELECT does not prove that every lower-risk person taking semaglutide gets the same heart-event reduction. It also does not mean semaglutide replaces statins, blood pressure treatment, smoking cessation, or standard cardiac care. Participants received usual cardiovascular risk management in both groups.
Stopping matters for risk markers
In the STEP 1 extension, participants who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost during the next year off treatment. Cardiometabolic improvements, including blood pressure, lipids, glucose markers, and inflammation markers, generally moved back toward baseline. That does not prove an immediate spike in heart attacks after stopping, but it does support treating obesity and cardiovascular risk as chronic conditions rather than short cycles of medication.
For a deeper discontinuation breakdown, see our guide to what happens when you stop GLP-1 drugs. For the broader non-weight-loss research picture, see GLP-1 benefits beyond weight loss.
Semaglutide vs. Other Weight Loss Peptides
Semaglutide was the breakthrough, but it's no longer the only option. Here's how it compares at a high level:
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg. Weight Loss | ~15% | ~22.5% | ~28.7% |
| FDA Approved | ✅ Yes | ✅ Yes | Phase 3 |
| Administration | Weekly injection or daily oral | Weekly injection | Weekly injection |
| Brand Names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | — |
vs. Orforglipron (Foundayo) — The First Oral Small-Molecule GLP-1
Orforglipron (brand name Foundayo) is a fundamentally different type of GLP-1 drug. While semaglutide is a peptide (injectable or large oral formulation), orforglipron is a small-molecule GLP-1 receptor agonist — a conventional pill taken once daily.
| Semaglutide (Wegovy) | Orforglipron (Foundayo) | |
|---|---|---|
| Mechanism | GLP-1 peptide agonist | Small-molecule GLP-1 agonist |
| Administration | Weekly injection or large oral pill (Rybelsus) | Once-daily pill (any time, no food restrictions) |
| Avg. weight loss | ~15% (standard); ~21% (7.2 mg HD) | ~14–16% in Phase 3 trials |
| Oral convenience | Limited — Rybelsus requires fasting 30 min | Superior — no fasting requirement |
| Can be compounded? | Yes (during shortages) | No — small molecules cannot be compounded like peptides |
Orforglipron represents a meaningful shift in patient choice — a daily pill with efficacy similar to injectable semaglutide and no injection barrier. See the orforglipron complete guide →
International Generics (2026)
In some international markets — particularly in parts of Asia and Latin America — semaglutide biosimilars and generics are beginning to reach patients as Novo Nordisk's patents expire in certain jurisdictions. These are distinct from compounded versions: they are approved drugs in their respective countries but have not been reviewed by the FDA. U.S. patients should not import these products, but their emergence is expected to accelerate global pricing pressure. See our compounded vs. brand guide for more on access and cost options.
Handling & storage
Storage at a glance
FDA label- Reconstituted
- 2 to 8°C
- Use within OZEMPIC multidose pen: 56 days after first use; WEGOVY single-dose presentations are used once
- Follow the exact brand and presentation. Do not apply the 56-day OZEMPIC rule to compounded vials.
- Light
- Protect from light. Do not freeze.
- Room temperature
- OZEMPIC may be stored for 56 days after first use at 15 to 30°C or 2 to 8°C. WEGOVY presentation-specific excursion rules differ, so use its current label.
- Reconstitution
- Follow product-specific instructions
- Not applicable to approved solution products.
- Half-life
- about 1 week
- humans after subcutaneous administration
Basis: FDA label. Sources: DailyMed OZEMPIC injection label, DailyMed WEGOVY label, DailyMed RYBELSUS/OZEMPIC tablets label
OZEMPIC is an approved multidose pen supplied as a solution. Store it at 2 to 8°C before use, protect it from light, and do not freeze. After first use, the OZEMPIC pen may be kept for 56 days at either 2 to 8°C or 15 to 30°C.
WEGOVY injections, WEGOVY tablets, and RYBELSUS have presentation-specific instructions, so follow the exact current label. The 56-day OZEMPIC rule does not establish a beyond-use date for compounded or research vials. Semaglutide has a human half-life of about 1 week after subcutaneous administration.
Safety & cautions
Semaglutide's side effects are well-documented from clinical trials involving thousands of participants. Most are gastrointestinal and tend to be worst during dose escalation.
Semaglutide carries a black box warning for thyroid C-cell tumors. In animal studies, GLP-1 receptor agonists caused thyroid tumors. It's unknown whether this applies to humans, but semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Dosing Protocol
Semaglutide for weight loss follows a gradual dose escalation to minimize gastrointestinal side effects. You don't start at the full dose — you build up over 16–20 weeks.
Standard Wegovy Escalation Schedule
| Weeks | Weekly Dose | Purpose |
|---|---|---|
| 1–4 | 0.25 mg | Initiation — body adjustment |
| 5–8 | 0.5 mg | First escalation |
| 9–12 | 1.0 mg | Second escalation |
| 13–16 | 1.7 mg | Third escalation |
| 17+ | 2.4 mg | Maintenance dose |
| (Advanced) | 7.2 mg | Wegovy HD — FDA approved March 2026 |
Ozempic Dosing (Off-Label for Weight Loss)
Ozempic's maximum approved dose is 2.0 mg/week (vs. Wegovy's 2.4 mg). When used off-label for weight loss:
| Weeks | Weekly Dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9+ | 1.0 mg (can increase to 2.0 mg) |
Side Effects
Semaglutide's side effects are well-documented from clinical trials involving thousands of participants. Most are gastrointestinal and tend to be worst during dose escalation.
Common (>10% of patients)
- Nausea — Most common; usually improves over weeks
- Diarrhea — Typically mild to moderate
- Vomiting — More common at higher doses
- Constipation — Can alternate with diarrhea
- Abdominal pain — Usually mild
Less Common (1–10%)
- Headache
- Fatigue
- Dizziness
- Bloating / gas
- Gastroesophageal reflux (heartburn)
- Hair thinning (from rapid weight loss, not the drug)
Serious Side Effects (Rare but Important)
- Pancreatitis — Seek immediate care for severe, persistent abdominal pain
- Gallbladder problems — Rapid weight loss increases gallstone risk
- Kidney injury — Usually from dehydration due to severe vomiting/diarrhea
- Hypoglycemia — Rare with semaglutide alone; possible with insulin or sulfonylureas
FDA Black Box Warning
Semaglutide carries a black box warning for thyroid C-cell tumors. In animal studies, GLP-1 receptor agonists caused thyroid tumors. It's unknown whether this applies to humans, but semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Managing Side Effects
- Follow the dose escalation schedule — don't rush it
- Eat smaller meals; avoid high-fat and greasy foods
- Stay well hydrated; eat slowly
- If nausea is severe, your doctor may slow the escalation
Cost and Access
Semaglutide access and pricing depends heavily on your path: brand-name prescription, compounded, or research.
Wegovy (weight loss)
- List price
- ~$1,349/month
- With insurance
- $0–$500/month
- Wegovy HD (7.2 mg)
- New, March 2026
Many insurance plans now cover Wegovy for obesity (BMI ≥30 or ≥27 with comorbidities). Novo Nordisk offers savings programs for eligible patients.
Ozempic (off-label)
- List price
- ~$935/month
- For diabetes
- Usually covered
- For weight loss
- Usually NOT covered
Compounded Semaglutide
During FDA-declared shortages, compounding pharmacies were allowed to produce semaglutide. This became a major access point (see our compounded vs. brand guide for the full breakdown):
- Typical cost: $150–$500/month depending on dose and provider
- Available through telehealth platforms (Hims, Ro, Found, etc.)
- Quality varies — look for FDA-registered facilities with Certificates of Analysis (COAs)
How to Access (Prescription Path)
- Talk to your doctor, or use a telehealth weight loss platform
- Get evaluated — typically requires BMI ≥30 or ≥27 with a weight-related condition
- If prescribed, fill through a pharmacy or the platform's partner pharmacy
Compare prices across telehealth platforms — costs vary widely. See our guide on finding the cheapest semaglutide online and tips for getting GLP-1s without insurance.
How to Get Semaglutide
Semaglutide requires a prescription. The most accessible route for most people is a telehealth provider. Below are platforms that currently offer semaglutide prescriptions.
PeptidePub may earn a commission from links below. See disclosure.
Eden Health
GLP-1 direct intake with clinician review
Useful starting point for visitors ready to discuss GLP-1 options with a licensed provider
SkinnyRx
Compounded injectable, tablet, and sublingual semaglutide options
Multiple semaglutide formats with dedicated GLP-1 landing pages
Medvi
Quiz-based weight-loss and GLP-1 intake flow
Good broad-funnel option, including Spanish and veteran landing pages for future campaigns
See our full provider comparison for more detail on pricing, what's included, and how to choose.
Watch Semaglutide prices
We'll email you when prices drop, a discount code changes, or new lab results come in for Semaglutide. No spam — only real changes.
Frequently asked questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist — a synthetic version of a naturally occurring hormone that regulates appetite and blood sugar. It is the active ingredient in Wegovy (weight loss) and Ozempic (type 2 diabetes), and was the first once-weekly injectable medication approved specifically for chronic weight management in adults with obesity.
How much weight can you lose on semaglutide?
Clinical trials show an average of ~15% body weight loss at the standard 2.4 mg dose over 68 weeks (STEP 1 trial). The newly approved 7.2 mg high-dose formulation (Wegovy HD) showed ~21% average weight loss in the STEP UP trial.
What are the side effects of semaglutide?
The most common side effects are gastrointestinal: nausea (affects up to 44% of patients), vomiting, diarrhea, and constipation. These are typically most pronounced during dose escalation and improve over time. Serious but rare side effects include pancreatitis and gallbladder disease.
How much does semaglutide cost?
Brand-name Wegovy costs approximately $1,350/month at list price without insurance. Compounded semaglutide from 503B-registered pharmacies through telehealth platforms typically costs $149–$299/month. With insurance coverage or manufacturer savings programs, brand-name costs can be lower.
Is there an oral semaglutide for weight loss?
Yes. As of January 2026, the FDA approved oral semaglutide (Rybelsus at higher doses) for chronic weight management — not just type 2 diabetes management. This makes semaglutide the first oral GLP-1 medication approved specifically for weight loss.
Does semaglutide reduce cardiovascular risk?
Yes, for a specific high-risk group. In SELECT, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and BMI of 27 or higher, without diabetes. The FDA approved Wegovy for this cardiovascular risk reduction indication in March 2024.
The Bottom Line
Semaglutide was the drug that proved medications could achieve meaningful, sustained weight loss. With ~15% average body weight reduction at standard doses — and up to 21% at the newly approved 7.2 mg Wegovy HD — it set a new standard for obesity treatment.
It's not perfect: it requires ongoing use, has notable GI side effects, and is expensive without insurance coverage. Newer dual- and triple-agonist peptides (tirzepatide, retatrutide) are showing even greater efficacy.
But for millions of people struggling with obesity, semaglutide has been genuinely life-changing. It's the most studied, most prescribed, and most accessible of the modern weight loss peptides — and for many people, it's a reasonable first option.
Source details
- 1.Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002.
- 2.Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." The Lancet. 2021;397(10278):971-984.
- 3.Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA. 2021;325(14):1414-1425.
- 4.Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nature Medicine. 2022;28:2083-2091.
- 5.STEP UP Trial Results. Presented at ADA Scientific Sessions 2025.
- 6.Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389(24):2221-2232.
- 7.U.S. Food and Drug Administration. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." March 8, 2024.
- 8.NICE Technology Appraisal TA1152. "Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity." 2026.
- 9.Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
- 10."Spotlight on the Mechanism of Action of Semaglutide." Current Issues in Molecular Biology (MDPI). 2024;46(12):872.
- 11."Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss." The American Journal of Medicine. 2025.
Research updates
Stay Updated on Peptide Research
New trial results, FDA updates, and dosing guides — delivered to your inbox.
Medical disclaimer
Sources
Last reviewed May 8, 2026. This guide is educational and research-focused, not medical advice. Semaglutide products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.